Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00158041 · ClinicalTrials.gov registry record · Phase 4
Subcutaneous Amifostine Safety Study
A Phase 4 study, sponsored by Mt. Sinai Medical Center, Miami.
- Completed
- Registry status
- Phase 4
- Development phase
- 452
- Enrollment target
NCT00158041: Completed Phase 4 study, sponsored by Mt. Sinai Medical Center, Miami.
NCT00158041 is a Phase 4 study that has completed, run by Mt. Sinai Medical Center, Miami. The registered enrollment target is 452 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00158041, a Phase 4 study, has completed, sponsored by Mt. Sinai Medical Center, Miami.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 452 participants
- Enrollment target
Study Summary
Amifostine is a radioprotective drug which is approved by the US FDA for administration prior to each radiation treatment using the intravenous route. The study evaluated the safety of amifostine administered subcutaneously. The four targeted toxicities were nausea/vomiting, hypotension, generalized skin rash, and injection-site skin reactions.
Interventions
- DRUG Amifostine administered subcutaneously
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 452 participants |
| Start Date | 2002-01 |
| Est. Completion | 2005-01 |
| Phase | Phase 4 |
What the finished NCT00158041 record still lists
NCT00158041 is an interventional study that assigns participants to a tested intervention. The registered 452 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 1 intervention - of which Amifostine administered subcutaneously is the first listed.
NCT00158041 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00158041 about?
NCT00158041 is a clinical study titled "Subcutaneous Amifostine Safety Study". Amifostine is a radioprotective drug which is approved by the US FDA for administration prior to each radiation treatment using the intravenous route. The study evaluated the safety of amifostine administered subcutaneously. The four targeted toxicities were nausea/vomiting, hypotension, generalized...
What is the current status of trial NCT00158041?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 452 participants. The study started on 2002-01. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00158041?
The interventions under investigation include: Amifostine administered subcutaneously (DRUG).
Who is sponsoring clinical trial NCT00158041?
This trial is sponsored by Mt. Sinai Medical Center, Miami, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00158041's enrollment target sits among peer trials
452 187th of 2000 higher than 1,814 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05676255 · 452 participants · Phase 2
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
- NCT05703178 · 452 participants · Phase 3
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
- NCT03460977 · 453 participants · Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- NCT04708171 · 453 participants
The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia